Stockreport

Chiasma Announces Positive Phase 3 Top-Line Results from CHIASMA OPTIMAL Clinical Trial of Mycapssa® for the Maintenance Treatment of Adults with Acromegaly

Chiasma, Inc  (CHMA) 
Last chiasma, inc earnings: 3/16 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: chiasmapharma.com/information-investors
PDF SPA-agreed trial met primary and all secondary endpoints No new or unexpected safety signals in the Mycapssa treated patients 90% of the patients treated with Mycapssa [Read more]